Pfizer said Wednesday that its gene therapy for hemophilia A successfully reduced patients’ bleeds for at least 15 months in a large Phase 3 trial.
The data may be enough to muster approval, but they are unlikely to quell doubts about whether the treatment can provide a cure — as had once been hoped — or a meaningful option for most patients in the U.S. and Europe with the rare blood disorder.
“There’s a primary endpoint, and then there’s what will predict meaningful commercial success,” said Lindsey George, head of in vivo gene therapy at Children’s Hospital of Philadelphia.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
